Professional
Technical
IVT
palivizumab
Pronunciation: pal-ih-VIZ-uh-mab
Monoclonal antibody prophylaxis against respiratory syncytial virus in high-risk infants.
Full Definition
Palivizumab is a humanized monoclonal antibody administered monthly during RSV season to prevent severe respiratory syncytial virus infection in high-risk infants. Indications include premature infants, children with chronic lung disease, and those with hemodynamically significant congenital heart disease. The medication is given as an intramuscular injection and provides passive immunity against RSV.
Usage
Usage note: Brand name Synagis may appear in clinical documentation; ensure consistency in terminology.
In Context
- "The premature infant was scheduled for monthly palivizumab injections during RSV season." — Treatment plan
- "Palivizumab prophylaxis reduced the risk of RSV hospitalization in the cohort." — Research abstract
Also known as
Synagis
Don't confuse with
ribavirin
oseltamivir